Work

Suppression of PARP1 enhances PTEN mRNA therapy in castration-resistant prostate cancer by glycolysis disruption

Year: 2026

Type: article

Abstract: . Mechanistically, the restoration of PTEN inhibited glycolysis via the PI3K-Akt signaling pathway in CRPC cells, and the silencing of PARP1 further enhanced this effect. Overall, the mPsiP@miLAND developed in this study effectively inhibited the growth of PTEN-deficient prostate tumors, providing a promising strategy to overcome CRPC by exploiting the synergistic effects of PI3K-Akt and PARP inhibition.

Source: Molecular Therapy Oncology

DOI: 10.1016/j.omton.2026.201133

Authors: Bo Hu, Pengfei Wu, Lulu Zheng, Haiyin Yang, Yuchuan Fan, Jun Yang, Lu Tang, Sudong Kong, Chao Zhu, Minghui Yang, Jiatao Zhang, Qing Liu, Yuanyu Huang

Institutions: Beijing Institute of Technology, Zhuhai People's Hospital, Universitätsklinikum Aachen, RWTH Aachen University, Shandong Academy of Agricultural Sciences, State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,900

Funders: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Beijing Institute of Technology, Taishan Scholar Project of Shandong Province, National University's Basic Research Foundation of China, Fundamental Research Funds for the Central Universities

Awards: G1562773926, G3695366359, G3916259866, G4662222179, G4945584486, G5877365754, G765609866, G8846909380

OpenAlex ID: W7124978557

FWCI: 4.618

Cites: 44

Cited by: 1

Related to: